Skip to content

Ketamine: all studies

Page 216 of 449: studies 2,151 to 2,160 of 4,486, newest first. Back to the ketamine overview

Research

Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property

Frontiers in Pharmacology February 26, 2021 Guy A. Higgins, Nicole K. Carroll, Matthew A. Brown et al. 67 citations

Long term benefits following short-term administration of high psychedelic doses of serotonergic and dissociative hallucinogens, typified by psilocybin and ketamine respectively, support their potential as treatments for psychiatric conditions such as major depressive disorder. The high psychedelic doses induce perceptual experiences which are associated with therapeutic benefit. There have...

Neuregulin signaling mediates the acute and sustained antidepressant effects of subanesthetic ketamine

Translational Psychiatry February 24, 2021 Steven F. Grieco, X. Qiao, Kevin Johnston et al.

Subanesthetic ketamine evokes rapid antidepressant effects in human patients that persist long past ketamine’s chemical half-life of ~2 h. Ketamine’s sustained antidepressant action may be due to modulation of cortical plasticity. We find that ketamine ameliorates depression-like behavior in the forced swim test in adult mice, and this depends on parvalbumin-expressing (PV) neuron-directed...

Ketamine and attentional bias to threat: dynamic causal modeling of magnetoencephalographic connectivity in treatment-resistant depression

medRxiv Preprint Server February 22, 2021 Jessica R. Gilbert, Christina S. Galiano, Allison C. Nugent et al. preprint

The glutamatergic modulator ketamine rapidly reduces depressive symptoms in individuals with treatment-resistant major depressive disorder (MDD) and bipolar disorder. While its underlying mechanism of antidepressant action is not fully understood, modulating glutamatergically-mediated connectivity appears to be a critical component moderating antidepressant response. This double-blind,...

Functional connectivity between the amygdala and subgenual cingulate gyrus predicts the antidepressant effects of ketamine in patients with treatment‐resistant depression

Neuropsychopharmacology Reports February 21, 2021 Tomoyuki Nakamura, Masaru Tomita, N. Horikawa et al. 29 citations

Approximately one‐third of patients with major depressive disorder develop treatment‐resistant depression. One‐third of patients with treatment‐resistant depression demonstrate resistance to ketamine, which is a novel antidepressant effective for this disorder. The objective of this study was to examine the utility of resting‐state functional magnetic resonance imaging for the prediction of...

Widespread Cortical Thickness Reductions Following Non-medical Use of Ketamine: a Structural MRI Study of Individuals with Ketamine Dependence

medRxiv Preprint Server February 21, 2021 Jinsong Tang, Qiuxia Wu, Chang Qi et al. preprint

Background A version of ketamine, called Esketamine has been approved for treatment-resistant depression (TRD). Ketamine (“K powder”), a “dissociative” anesthetic agent, however, has been used non-medically alone or with other illicit substances. Our previous studies showed a link between non-medical ketamine use and brain structural and functional alterations. We found dorsal prefrontal gray...

DOI: 10.1101/2021.02.21.21252178 (opens in new tab) Full text (opens in new tab) Ketamine abuse Recreational ketamine use Illicit ketamine Ketamine dependence +11

Ketamine—50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms

Pharmacological Reports February 20, 2021 Samuel Kohtala

Over the past 50 years, ketamine has solidified its position in both human and veterinary medicine as an important anesthetic with many uses. More recently, ketamine has been studied and used for several new indications, ranging from chronic pain to drug addiction and post-traumatic stress disorder. The discovery of the rapid-acting antidepressant effects of ketamine has resulted in a surge of...

Ketamine disrupts gaze patterns during face viewing in the common marmoset

bioRxiv Preprint Server February 16, 2021 Janahan Selvanayagam, Kevin Johnston, Raymond K. Wong et al. preprint

Faces are stimuli of critical importance for primates. The common marmoset (Callithrix jacchus) is a promising model for investigations of face processing, as this species possesses oculomotor and face processing networks resembling those of macaques and humans. Face processing is often disrupted in neuropsychiatric conditions such as schizophrenia (SZ) and thus it is important to recapitulate...

DOI: 10.1101/2021.02.16.431438 (opens in new tab) Full text (opens in new tab) Ketamine: substances Social behavior Face-viewing Visual attention +3

The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women: Quantification of ketamine and metabolites

February 13, 2021 Philip E. Wolfson, Rob Cole, Kara L. Lynch et al. 5 citations

Abstract: There is no available data on the secretion and concentration of ketamine and its metabolites in breastmilk. There are statements in the literature made as to the safety of the use of ketamine in lactating women, though these are unsupported. This information is pertinent for the treatment of breastfeeding women who may have depression, PTSD, postpartum depression, and other emotional...

Ketamine and the Future of Rapid-Acting Antidepressants

Annual Review of Clinical Psychology February 9, 2021 L. Riggs, T. Gould 87 citations

The therapeutic onset of traditional antidepressants is delayed by several weeks and many depressed patients fail to respond to treatment altogether. In contrast, subanesthetic ketamine can rapidly alleviate symptoms of depression within hours of a single administration, even in patients who are considered treatment-resistant. Ketamine is thought to exert these effects by restoring the...

Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression

arXiv Preprint Archive February 4, 2021 Erik D. Fagerholm, Robert Leech, Steven C. R. Williams et al. preprint

The glutamatergic modulator ketamine has been shown to rapidly reduce depressive symptoms in patients with treatment-resistant major depressive disorder (TRD). Although its mechanisms of action are not fully understood, changes in cortical excitation/inhibition (E/I) following ketamine administration are well documented in animal models and could represent a potential biomarker of treatment...

Full text (opens in new tab) Q-bio.qm Depression treatment Ketamine therapy Brain imaging